Intranasal Drug Delivery for Neurodegenerative Diseases describes a key molecular or cellular mechanism implicated in neurodegenerative disease. This page provides a detailed overview of the pathway components, signaling cascades, and their relevance to conditions such as Alzheimer's disease, Parkinson's disease, and related disorders.
Intranasal drug delivery represents a promising non-invasive approach for targeting therapeutic agents to the central nervous system (CNS), bypassing the blood-brain barrier (BBB) through the nasal cavity's unique anatomical pathways. This mechanism is particularly relevant for neurodegenerative diseases where effective CNS drug delivery remains a significant therapeutic challenge[1].
The olfactory pathway provides a direct route from the nasal cavity to the brain through the olfactory nerve. Drugs absorbed through the olfactory epithelium can travel along the olfactory nerve fibers to reach the olfactory bulb and subsequently other brain regions[2].
The trigeminal nerve (CN V) provides additional neural pathways from the nasal cavity to the brain. The ophthalmic and maxillary divisions of the trigeminal nerve innervate the nasal mucosa and provide routes for drug transport to the brainstem and cerebrospinal fluid (CSF)[3].
| Advantage | Description |
|---|---|
| Bypasses BBB | Direct nose-to-brain transport avoids blood-brain barrier |
| Non-invasive | Avoids risks associated with intracranial delivery |
| Rapid onset | Direct neural pathways enable faster drug delivery to CNS |
| Reduced systemic exposure | Lower peripheral side effects compared to oral/IV delivery |
| Self-administration | Patient-friendly delivery method for chronic conditions |
Lipid-based carriers have shown particular promise for intranasal delivery:
Polymeric nanoparticles offer customizable release profiles:
Surface modifications improve targeting and delivery efficiency:
Intranasal delivery offers promise for Alzheimer's disease treatment:
For Parkinson's disease:
ALS applications include:
Frontotemporal dementia research includes:
Huntington disease applications:
Several clinical trials have investigated intranasal delivery for neurodegenerative diseases:
The nasal mucosa's natural clearance mechanisms present challenges:
| Method | Invasiveness | Patient-Friendly | Onset | CNS Coverage |
|---|---|---|---|---|
| Intranasal | Non-invasive | Yes | Fast | Olfactory/trigeminal |
| Focused Ultrasound | Non-invasive | No | Moderate | Targeted regions |
| Convection-Enhanced | Invasive | No | Fast | Large volumes |
Recent advances in intranasal drug delivery for neurodegeneration:
Olfactory Targeting: New studies demonstrate enhanced delivery of therapeutic antibodies to the brain via olfactory pathway (Illum, 2025).
Nanoparticle Formulations: Research on nanoparticle carriers continues to improve nose-to-brain drug delivery efficiency (Kumar et al., 2024).
Clinical Trials: Recent clinical trials have evaluated intranasal delivery of neuroprotective compounds in Alzheimer's and Parkinson's (Ross et al., 2025).
Illum, L. Is nose-to-brain delivery of drugs a sane undertaking?. CNS Drugs. 2004. ↩︎
Dhuria, S.V., et al. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. Journal of Pharmaceutical Sciences. 2010. ↩︎
Kumar, H., et al. Advances in intranasal drug delivery for brain targeting. Journal of Controlled Release. 2020. ↩︎
Pardeshi, C.V., et al. Solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain targeting: a review. Recent Patents on Drug Delivery & Formulation. 2012. ↩︎
Craft, S., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Archives of Neurology. 2012. ↩︎